camrelizumab

5 · 20 / page

Ask MedXY AI

Latest news

Tag

Clinical Updatescamrelizumabimmunotherapy

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

By MedXY|Mar 20, 2026

This review analyzes the 5-year overall survival outcomes of the CAPTAIN-1st trial, establishing camrelizumab plus chemotherapy as a long-term standard of care for recurrent or metastatic nasopharyngeal carcinoma.

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

newscamrelizumabimmunotherapy

camrelizumab

Latest news

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

Perioperative Camrelizumab Plus Rivoceranib Enhances Event-Free Survival in High-Risk Resectable Hepatocellular Carcinoma

Advancing Adjuvant Therapy in Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Promising Results from Immunochemoradiation Trial